Forced Oscillometry in Infants with Bronchopulmonary Dysplasia
Launched by WINSTON MANIMTIM · Feb 12, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called forced oscillometry (FOT) to better understand how the lungs work in infants with a condition known as bronchopulmonary dysplasia (BPD). BPD often affects premature babies and can lead to breathing difficulties. The researchers want to see how well this technique can measure lung function in both premature infants with BPD and term infants who do not have any lung issues.
If you have a premature baby with BPD who is breathing room air or receiving a small amount of oxygen but can breathe without assistance for short periods, they might be eligible to participate in this study. Additionally, healthy infants older than 36 weeks who are less than 4 weeks old may also join. During the trial, participants will undergo non-invasive tests to check their lung function, which means there won't be any uncomfortable procedures involved. This study is currently looking for participants, and it aims to help improve the understanding and treatment of breathing problems in infants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Preterm Cohort:
- • Premature infants with BPD who are in room air based on the (per NICHD definition)
- • Premature infants with BPD who are receiving low flow O2 support and able to maintain normal spO2 in Room air for brief period ( up to 3 minutes) Term Cohort without pulmonary disease
- • Infants \>36 weeks gestational age without pulmonary disease
- • Infants \< 4 weeks of age
- Outpatient Cohort:
- • Former preterm infants \< 32 weeks at birth
- • Those with BPD based on NIH 2001 definition
- • Seen prior to 2 years of age
- Exclusion Criteria:
- • Infants with BPD requiring invasive or non-invasive positive pressure ventilation
- • Infants with BPD who have associated genetic diagnosis or major congenital anomalies.
About Winston Manimtim
Winston Manimtim is a dedicated clinical trial sponsor with a focus on advancing innovative therapies to improve patient outcomes. With a commitment to rigorous scientific standards and ethical practices, the organization collaborates with leading research institutions and healthcare professionals to conduct meticulously designed clinical studies. Winston Manimtim prioritizes patient safety and data integrity, ensuring that each trial is aligned with regulatory requirements and best practices in clinical research. Through its strategic initiatives, the sponsor aims to accelerate the development of groundbreaking treatments across various therapeutic areas, ultimately contributing to the advancement of medical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kansas City, Missouri, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials